Literature DB >> 4027319

Testing for qualitative interactions between treatment effects and patient subsets.

M Gail, R Simon.   

Abstract

Evaluation of evidence that treatment efficacy varies substantially among different subsets of patients is an important feature of the analysis of large clinical trials. Qualitative or crossover interactions are said to occur when one treatment is superior for some subsets of patients and the alternative treatment is superior for other subsets. A non-crossover interaction arises when there is variation in the magnitude, but not in the direction, of treatment effects among subsets. Some authors use the term quantitative interaction to mean non-crossover interaction. Non-crossover interactions are usually of less clinical importance than qualitative interactions, which often have major therapeutic significance. A likelihood ratio test is developed to test for qualitative interactions. Exact critical values are determined and tabulated.

Entities:  

Mesh:

Year:  1985        PMID: 4027319

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  105 in total

1.  Interaction trees with censored survival data.

Authors:  Xiaogang Su; Tianni Zhou; Xin Yan; Juanjuan Fan; Song Yang
Journal:  Int J Biostat       Date:  2008-01-28       Impact factor: 0.968

2.  Mortality in the randomized, controlled lung intergroup trial of isotretinoin.

Authors:  J Jack Lee; Lei Feng; Daniel S Reshef; Anita L Sabichi; Brendell Williams; Waree Rinsurongkawong; Ignacio I Wistuba; Reuben Lotan; Scott M Lippman
Journal:  Cancer Prev Res (Phila)       Date:  2010-05-25

3.  Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART.

Authors:  Sarah A Kelleher; Caroline S Dorfman; Jen C Plumb Vilardaga; Catherine Majestic; Joseph Winger; Vicky Gandhi; Christine Nunez; Alyssa Van Denburg; Rebecca A Shelby; Shelby D Reed; Susan Murphy; Marie Davidian; Eric B Laber; Gretchen G Kimmick; Kelly W Westbrook; Amy P Abernethy; Tamara J Somers
Journal:  Contemp Clin Trials       Date:  2017-04-11       Impact factor: 2.226

4.  Gene-environment interactions in cancer epidemiology: a National Cancer Institute Think Tank report.

Authors:  Carolyn M Hutter; Leah E Mechanic; Nilanjan Chatterjee; Peter Kraft; Elizabeth M Gillanders
Journal:  Genet Epidemiol       Date:  2013-10-05       Impact factor: 2.135

5.  Relationships between genotype x environment interactions and rank orders for a set of genotypes tested in different environments.

Authors:  M Hühn; S Lotito; H P Piepho
Journal:  Theor Appl Genet       Date:  1993-09       Impact factor: 5.699

6.  Interference effects in white clover genotypes grown as pure stands and binary mixtures with different grass species and varieties.

Authors:  P Annicchiarico; E Piano
Journal:  Theor Appl Genet       Date:  1994-05       Impact factor: 5.699

7.  Subgroup identification from randomized clinical trial data.

Authors:  Jared C Foster; Jeremy M G Taylor; Stephen J Ruberg
Journal:  Stat Med       Date:  2011-08-04       Impact factor: 2.373

Review 8.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects.

Authors:  David M Kent; Ewout Steyerberg; David van Klaveren
Journal:  BMJ       Date:  2018-12-10

9.  Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.

Authors:  J Pater; L Slamet; B Zee; D Osoba; D Warr; J Rusthoven
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

10.  Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US.

Authors:  Virginia M Rosen; Douglas C A Taylor; Hemangi Parekh; Ankur Pandya; David Thompson; Andreas Kuznik; David D Waters; Michael Drummond; Milton C Weinstein
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.